MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ekir.2025.01.029

Медицинская библиотека · Kidney international reports · 2025

Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD.

Chan Bernard, Varghese Amanda, Badve Sunil V, Pecoits-Filho Roberto, Guedes Murilo, Arnott Clare, Kozor Rebecca, O'Lone Emma, Jun Min, Kotwal Sradha, Block Geoffrey A, Chertow Glenn M, Solomon Scott D, Vaduganathan Muthiah, Perkovic Vlado, Neuen Brendon L

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Heart failure and chronic kidney disease (CKD) are closely associated, and iron deficiency is highly prevalent in both conditions. However, major cardiovascular and nephrology guidelines offer contrasting recommendations for iron use. We evaluated the effects of iron versus usual care or placebo on the clinical outcomes in patients with CKD.

METHODS

We conducted a systematic review and meta-analysis of randomized trials on i.v. or oral iron in patients with CKD (PROSPERO CRD42023453468). We searched Medline, Embase, and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined the overall results and stratified them by dialysis- and nondialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. The primary composite endpoint was hospitalization for heart failure or cardiovascular death.

RESULTS

We identified 45 trials that met the inclusion criteria. Compared with usual care or placebo, iron reduced the risk of the primary composite endpoint (1659 events; risk ratio [RR]: 0.84, 95% confidence interval [CI]: 0.75-0.94; moderate certainty), an effect consistent across dialysis and nondialysis requiring CKD (P-heterogeneity = 0.70). The effect on the primary endpoint appeared driven by both components of hospitalization for heart failure (RR: 0.77; 95% CI: 0.61-0.96; moderate certainty) and cardiovascular death (RR: 0.81; 95% CI: 0.65-1.02; low certainty). The incidence of serious adverse events was lower for iron compared with usual care or placebo (RR: 0.90, 95% CI: 0.82-0.98; moderate certainty; P-heterogeneity = 0.09).

CONCLUSION

Iron therapy may reduce the risk of heart failure and cardiovascular death in patients with CKD. Randomized trials evaluating the effects of iron on clinical outcomes are needed, especially in nondialysis patients with CKD with or without anemia.

Для цитирования: Chan Bernard, Varghese Amanda, Badve Sunil V, Pecoits-Filho Roberto, Guedes Murilo, Arnott Clare, Kozor Rebecca, O'Lone Emma, Jun Min, Kotwal Sradha, Block Geoffrey A, Chertow Glenn M, Solomon Scott D, Vaduganathan Muthiah, Perkovic Vlado, Neuen Brendon L. Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD.. Kidney international reports. 2025. DOI: 10.1016/j.ekir.2025.01.029.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.